ARWR vs. AXTI

Last updated Apr 1, 2026

Compare and contrast key facts about Arrowhead Pharmaceuticals, Inc. (ARWR) and AXT, Inc. (AXTI).

Performance

ARWR vs. AXTI - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arrowhead Pharmaceuticals, Inc. (ARWR) and AXT, Inc. (AXTI). The values are adjusted to include any dividend payments, if applicable.

ARWR vs. AXTI - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ARWR Arrowhead Pharmaceuticals, Inc.	-5.56%	253.14%	-38.56%	-24.56%	-38.82%	-13.59%	20.97%	410.71%	237.50%	137.42%
AXTI AXT, Inc.	248.50%	653.46%	-9.58%	-45.21%	-50.28%	-7.94%	120.00%	-0.00%	-50.00%	81.25%

Fundamentals

Market Cap ARWR : $8.82B AXTI : $2.55B
EPS ARWR : $1.46 AXTI : -$0.48
PS Ratio ARWR : 7.96 AXTI : 28.41
PB Ratio ARWR : 15.52 AXTI : 9.45
Total Revenue (TTM) ARWR : $1.09B AXTI : $88.33M
Gross Profit (TTM) ARWR : $1.08B AXTI : $11.24M
EBITDA (TTM) ARWR : $360.26M AXTI : -$14.38M

Returns By Period

In the year-to-date period, ARWR achieves a -5.56% return, which is significantly lower than AXTI's 248.50% return. Over the past 10 years, ARWR has underperformed AXTI with an annualized return of 29.03%, while AXTI has yielded a comparatively higher 36.43% annualized return.

ARWR

• 1D: 8.76%
• 1M: -0.90%
• YTD: -5.56%
• 6M: 81.79%
• 1Y: 392.15%
• 3Y*: 35.15%
• 5Y*: -1.34%
• 10Y*: 29.03%

AXTI

• 1D: 8.06%
• 1M: 50.34%
• YTD: 248.50%
• 6M: 1,169.04%
• 1Y: 3,941.13%
• 3Y*: 142.82%
• 5Y*: 35.86%
• 10Y*: 36.43%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ARWR vs. AXTI — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARWR

ARWR Risk / Return Rank: 99
ARWR Sharpe Ratio Rank: 99
ARWR Sortino Ratio Rank: 98
ARWR Omega Ratio Rank: 97
ARWR Calmar Ratio Rank: 99
ARWR Martin Ratio Rank: 99

AXTI

AXTI Risk / Return Rank: 100
AXTI Sharpe Ratio Rank: 100
AXTI Sortino Ratio Rank: 99
AXTI Omega Ratio Rank: 99
AXTI Calmar Ratio Rank: 100
AXTI Martin Ratio Rank: 100

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ARWR vs. AXTI - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Arrowhead Pharmaceuticals, Inc. (ARWR) and AXT, Inc. (AXTI). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ARWR	AXTI	Difference
Sharpe ratio Return per unit of total volatility	5.59	32.68	-27.08
Sortino ratio Return per unit of downside risk	4.63	6.95	-2.33
Omega ratio Gain probability vs. loss probability	1.60	1.86	-0.26
Calmar ratio Return relative to maximum drawdown	14.35	102.50	-88.15
Martin ratio Return relative to average drawdown	39.33	305.89	-266.56
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ARWR vs. AXTI - Sharpe Ratio Comparison

The current ARWR Sharpe Ratio is 5.59, which is lower than the AXTI Sharpe Ratio of 32.68. The chart below compares the historical Sharpe Ratios of ARWR and AXTI, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ARWR	AXTI	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	5.59	32.68	-27.08
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.02	0.40	-0.42
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.39	0.46	-0.07
Sharpe Ratio (All Time) Calculated using the full available price history	-0.01	0.08	-0.09

Correlation

The correlation between ARWR and AXTI is 0.15, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ARWR vs. AXTI - Dividend Comparison

Neither ARWR nor AXTI has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

ARWR vs. AXTI - Drawdown Comparison

The maximum ARWR drawdown since its inception was -99.24%, roughly equal to the maximum AXTI drawdown of -98.57%. Use the drawdown chart below to compare losses from any high point for ARWR and AXTI.

Drawdown Indicators

	ARWR	AXTI	Difference
Max Drawdown Largest peak-to-trough decline	-99.24%	-98.57%	-0.67%
Max Drawdown (1Y) Largest decline over 1 year	-24.64%	-36.59%	+11.95%
Max Drawdown (5Y) Largest decline over 5 years	-88.94%	-90.65%	+1.71%
Max Drawdown (10Y) Largest decline over 10 years	-88.96%	-92.45%	+3.49%
Current Drawdown Current decline from peak	-61.42%	-16.74%	-44.68%
Average Drawdown Average peak-to-trough decline	-81.40%	-82.78%	+1.38%
Ulcer Index Depth and duration of drawdowns from previous peaks	8.99%	12.26%	-3.27%

Volatility

ARWR vs. AXTI - Volatility Comparison

The current volatility for Arrowhead Pharmaceuticals, Inc. (ARWR) is 16.63%, while AXT, Inc. (AXTI) has a volatility of 49.61%. This indicates that ARWR experiences smaller price fluctuations and is considered to be less risky than AXTI based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ARWR	AXTI	Difference
Volatility (1M) Calculated over the trailing 1-month period	16.63%	49.61%	-32.98%
Volatility (6M) Calculated over the trailing 6-month period	46.06%	100.03%	-53.97%
Volatility (1Y) Calculated over the trailing 1-year period	71.17%	122.61%	-51.44%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.68%	91.12%	-26.44%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	74.13%	79.43%	-5.30%

Financials

ARWR vs. AXTI - Profitability Comparison

The chart below illustrates the profitability comparison between Arrowhead Pharmaceuticals, Inc. and AXT, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ARWR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a gross profit of 264.03M and revenue of 264.03M. Therefore, the gross margin over that period was 100.0%.

AXTI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported a gross profit of 4.83M and revenue of 23.04M. Therefore, the gross margin over that period was 21.0%.

ARWR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported an operating income of 40.81M and revenue of 264.03M, resulting in an operating margin of 15.5%.

AXTI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported an operating income of -3.83M and revenue of 23.04M, resulting in an operating margin of -16.6%.

ARWR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Arrowhead Pharmaceuticals, Inc. reported a net income of 30.81M and revenue of 264.03M, resulting in a net margin of 11.7%.

AXTI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, AXT, Inc. reported a net income of -3.55M and revenue of 23.04M, resulting in a net margin of -15.4%.